Issue link: http://osercommunicationsgroup.uberflip.com/i/709455
C h a i n D r u g s t o r e D a i l y 7 7 M o n d a y, A u g u s t 8 , 2 0 1 6 progress toward the new health targets established in the United Nations Sustainable Development Goals. This recognition was led by PATH and sup- ported by the Bill & Melinda Gates Foundation and USAID, among others. DiaResQ is a different kind of diar- rhea relief because it's not a drug or antibiotic. It's a food made from natural- ly derived ingredients that reach the intestine to rapidly restore normal func- tion. It is a safe, gentle, effective solution for children as young as one year old. Easy to use DiaResQ packets have been used in the toughest environments. Originally developed to address a major health concern in places like India and China, DiaResQ is also effective for less severe cases of diarrhea. Diarrhea is not just a problem in developing countries; it is also an issue here in the United States. Every year there are approximately 45 million episodes in children under five years of age. In fact, children in the U.S. will have had seven to 15 episodes of diarrhea by age five (Johns Hopkins Medicine, Diarrhea in Children). When it comes to adults, approximately 179 million cases of diarrhea occur each year in the U.S. (The New England Journal of Medicine, Acute Infectious Diarrhea in Immunocompetent Adults). P anTheryx (C o nt'd. fro m p. 1 ) DiaResQ is a must-have at home, but also for travel. When traveling, be pre- pared. Don't let an episode of diarrhea ruin your vacation or trip. According to the Centers for Disease Control (CDC), diarrhea attack rates range from 30 per- cent to 70 percent of travelers, depending on the destination and season of travel. Thanks to a new partnership with Passport Health Clinics, travelers now have access to DiaResQ. Passport Health is the largest and leading provider of travel medicine and vaccination services in North America, with more than 250 clinics nationwide. "This new and innovative product will greatly benefit business and leisure travelers," said Carrie Falbe, Director of Product and Service Development for Passport Health. "We are very excited to make DiaResQ the cornerstone of our traveler's diarrhea standard of care." About PanTheryx PanTheryx is a Boulder, Colorado based company that innovates with a focus on improving global health and quality of life. Its mission includes ensuring that the most at risk populations have access to the benefits of its products. Visit PanTheryx, Inc. at booth #1956. For more information, go to www.diaresq.com and www.pantheryx.com. MR: My goal is to raise awareness of the improvements that IMS Health, our new owner, is making to the legacy Healthcare Data Solutions (HDS) phar- macy products. IMS is the largest data provider in the world and they believe strongly in what HDS has built for the pharmacy space. We have been working the past year to integrate and enhance, and now we are ready to showcase the work we have done. CDD: Can you elaborate on "enhance"? MR: We looked at the data attributes that are important for pharmacy compliance needs. We identified relevant prescriber attributes that IMS Health had but HDS did not, and vice versa and we applied the unique business rules to the data that HDS had previously implemented. We expect to deliver our first fully enhanced prescriber product at the end of 2016. CDD: Who is IMS Health? MR: From a pharmacy perspective, IMS Health has focused on working with pharmacies to identify prescription trends in the market. They are the largest provider of prescription data in the world. That data is used for many appli- cations. IMS has backed and supported HDS' pharmacy initiative and committed both financially and strategically to ensure our success. CDD: What are your solutions for phar- macy retailers? MR: We help pharmacies with provider compliance concerns. Providers can mean employees that are pharmacists, or physicians that are writing prescriptions to be filled at the pharmacy. Those con- cerns are about the validity of state licen- sure, DEA numbers, NPI numbers, sanc- tions, exclusions and more. CDD: Tell our readers about your four core products for pharmacy. MR: The first one, Medical License I MS H ealth (C o nt'd. fro m p. 1 ) Monitor (MLM), is focused on the employee. It is a tool used by HR depart- ments or pharmacy operations to monitor their people and ensure they are in good standing and able to fill a prescription. The second product is known as Central Prescriber (CP). It's a database that can be accessed either through a file transfer or API. It is used by pharmacies during the prescription entry step to identify a doctor and create a new doctor record within a pharmacy system. Our third product has been renamed from Prescriber Validation Subscription Service (PVSS) to Central Prescriber Validation (CPV). This enables the phar- macy, prior to adjudicating the prescription to the insurance plan, to ensure the pre- scriber may legally prescribe the drug that was written. The fourth product is OneKey Web (former HDSverify). It allows anyone to do an ad-hoc lookup of a provider at any time. It is mostly used by corporate offices and independent pharmacies. CDD: Which of these products are you highlighting at Total Store Expo? MR: We are proud to announce the release of version 2 of MLM at the show. Version 2 has a new user interface. You are now able to monitor DEA, NPI and PTCB licenses for pharmacy certifica- tion. These enhancements further support the evolving role of the pharmacist and ensure that technicians are in active and good standing. CDD: What is the impact of not verify- ing provider credentials? MR: As published in our recent whitepa- per, the fines are enormous. A single instance of not validating a DEA number may cost a pharmacy $25,000. An analysis of Validation messages by HDS from January 2016 to June 10, 2016 shows that pharmacy clients received 351,693 mes- sages regarding invalid DEA numbers. This equates to almost $8.8M in fine avoidance! For more details, please download our white paper at www.skainfo .com/whitepapers/annual-pharmacy-report. For more information, visit booth #418. SMART Temps LLC, founded in 2004 and located in Mishawaka, Indiana, specializes in temperature monitoring solutions for increased compliance, loss prevention and patient safety. SMART Temps partners with more than 14,000 locations nationwide, providing a solu- tion exceeding CDC Guidelines on Vaccine Storage and Handling (June 2016), as well as various state require- ments and standards. This automated temperature monitoring system logs tem- peratures 24/7, removing the manual process. The wireless system alerts dur- ing any temperature excursion or power outage via text/email/phone call. The reporting tool is completely web-based, allowing real time remote access from anywhere. The SMART Temps equip- ment has the ability to communicate via ethernet, Wi-Fi or even cellular. Josh Griggs, MBA, Director of Healthcare Sales, says, "The target audi- ence for SMART Temps is pharmacy and clinical administration, along with indi- viduals who manage compliance or facili- ty management. We are most proud of the product we provide and the customer base we manage. Currently, we monitor and manage just north of 14,000 locations SMA R T Temps (C o nt'd. fro m p. 1 ) nationwide, including more than 6,000 retail pharmacies. We have a proven track record, with the ability to implement and manage the largest to the smallest organi- zations. Not to mention, our in-house Customer Support Specialists are always available for questions or assistance." Because SMART Temps frees its customers from a manual logging process, a huge productivity enhance- ment is provided. In addition, the alerting tool not only delivers a large ROI, which prevents inventory loss, it also facilitates the efficacy of inventory, thus ensuring that the client's inventory is never com- promised. As a result, SMART Temps pharmacy customers and patients have peace of mind regarding the integrity of the medications/vaccines they receive. Griggs continues, "NACDS allows us to network with all of our current and potential partners. Our main goal is to learn more about the specific needs of our partners, which enables us to provide the solution most suitable for the specific pharmacy environment." SMART Temps offers a free 30-day trial. For more information, visit booth #2121, call 877.272.3111, x160, email josh@smart-temps.com or go to www.smart-temps.com. PAIN THERAPEUTICS RESUBMITS REMOXY TO FDA Pain Therapeutics, Inc. announced today that it has resubmitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for REMOXY ® , an abuse-deterrent formula- tion of extended-release oxycodone (CII) capsules. Pain Therapeutics expects to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review designation. REMOXY is a proprietary drug developed and owned by Pain Therapeutics. The drug candidate's pro- posed indication is for "the management of pain severe enough to require daily, around-the-clock, long-term opioid treat- ment and for which alternative treatment options are inadequate." Pain Therapeutics specifically devel- oped REMOXY to make oxycodone dif- ficult to abuse yet provide 12 hours of steady pain relief when used appropriate- ly by patients. In particular, REMOXY's thick, sticky, high-viscosity formulation may deter unapproved routes of drug administration, such as injection, snort- ing or smoking. Pain Therapeutics owns exclusive, worldwide rights to REMOXY. About Opioid Abuse Opioid drugs such as oxycodone are an important treatment option for patients with severe chronic pain. However, oxy- codone abuse and diversion remains a serious, persistent problem. Nearly 19,000 people died from opioid overdose in 2014, according to the National Institute on Drug Abuse. For more than a decade, Pain Therapeutics has pioneered Abuse- Deterrent Formulations (ADFs) to help in the fight against prescription drug abuse. ADFs attempt to raise the bar on prescrip- tion drug abuse by making it difficult, longer or aversive to tamper with long- acting opioid formulations, recognizing that no drug can be made abuse-proof. About Pain Therapeutics, Inc. Pain Therapeutics develops proprietary drugs that offer significant improvements to patients and physicians. Its expertise consists of developing new drugs and guiding these through various regulatory and development pathways in prepara- tion for their eventual commercialization. It generally focuses its drug development efforts around disorders of the nervous system, such as chronic pain. The FDA has not yet established the safety or effi- cacy of its drug candidates.